04.12.25 -- Clinical Leader Best Of March

The U.S. FDA issued a draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, on January 6, 2025. The public comment period ends April 7.

Eduardo F. Motti, MD discusses patient payment from a global perspective, arguing that patient payment isn't thought of the same way around the world as it is in the U.S.

Walgreen’s new $25 million deal with BARDA (Biomedical Advanced Research and Development Authority) is a huge win for the pharmacy chain. John Campbell, head of DCTs at Walgreens, explains the ins and outs of the study and what could be next for the company regarding its clinical trials division.

Take action to improve diversity in clinical trials by addressing underrepresentation and ensuring equitable access to medical interventions, as emphasized by the FDA’s new 2025 guidance.

Unlock the potential of electronic Patient Reported Outcomes (ePRO) in your clinical research by implementing these essential best practices for success.

As protocols and studies become more complex, using technology to offer sites in-depth expertise and guidance is more important than ever to launch studies on time.